GLP-1R agonists were developed as long-acting therapeutic agents to overcome the short half-life of endogenous GLP-1, namely Semaglutide (Ozempic, Wegovy, Rybelsus)
Practical decision-making: Which should I consider? If your goal is metabolic disease treatment (obesity, insulin resistance, prediabetes, type 2 diabetes risk) GLP-1 (or related incretin therapy) tends to be the evidence-based anchor, paired with lifestyle and behavior architecture
Digital ERP tools: App-based Exposure and Response Prevention (ERP) platforms now integrate real-time therapist coaching with between-session exercises, making evidence-based ERP more accessible outside weekly office visits
Of course, those who want to benefit from the peptides should understand how they work, along with potential side effects, how to properly use the peptides, and where to easily purchase PT-141
Time allotted for each presentation may be limited